Johnson and Johnson
Amgen’s Otezla holds its ground against BMS’ Sotyktu in oral plaque psoriasis market, leaving room for J&J’s potential game-changer
Anika Sharma
Amgen’s bold $13.4 billion investment in Otezla appears to remain robust in the face of competition from Bristol Myers Squibb’s ...
